Potency of Combination of Fucoidan Microsphere and MiRNA-200b as Therapy in Chemoresistant Breast Cancer
DOI:
https://doi.org/10.28932/jmh.v2i5.1102Abstract
Breast cancer still become a major health problem in Indonesia and worldwide until today. Based on WHO 2012, breast cancer incidence is reported as 1.67 million cases with 90% of mortality rate in the metastasis stage. Chemoresistant is one cause of this increased mortality and morbidity. Nowadays, there are many treatment choices for cancer, but 90% incident of chemoresistant breast cancer occur even with prior chemotherapy. This review aimed to describe the potential of microsphere combinations fucoidan and miRNA-200b as a treatment for chemoresistant in breast cancer. Literature review were derived from scientific journals using www.pubmed.com and scholar.google.com database with “chemoresistant breast cancer, Fucoidan, microRNA-200b” as keyword. Fucoidan can induce apoptosis through the extrinsic pathway involving apoptotic receptor, or intrinsic pathway involving changes in mitochondrial membrane potential (MMP) to release cytochrome C and activating the apoptotic signal. Meanwhile, miRNA-200b expression, will decrease Sp1 expression and decrease histone-3 acetylation level in a miRNA-200b promoter, resulting in decreased cancer cell migration and invasion. However, no studies have evaluated this combination clinically. So, further studies are needed to confirm the potential of microsphere combination fucoidan and miRNA-200b in chemoresistant breast cancer. Keywords: chemoresistant breast cancer; Fucoidan; miRNA-200b.Downloads
Download data is not yet available.
Downloads
Published
2020-02-27
How to Cite
1.
Wiranata S, Yani MV, Satyarsa ABS, Ardiana IKR, Adiputra PA. Potency of Combination of Fucoidan Microsphere and MiRNA-200b as Therapy in Chemoresistant Breast Cancer. J. Med. Health [Internet]. 2020Feb.27 [cited 2024Dec.18];2(5). Available from: http://114.7.153.31/index.php/jmh/article/view/1102
Issue
Section
Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain the copyright and grant the journal right of first publication with the work
simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.